Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...

Key opinion leaders provide their final thoughts on treatment management for patients with MDS. Ryan Haumschild, PharmD, MS, MBA: Thank you for this rich and informative discussion. Before we conclude ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

DUBLIN, June 17, 2021 /PRNewswire/ -- The "Myelodysplastic Syndrome (MDS) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of ...

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Geron is planning to submit a New Drug Application (NDA) for imetelstat, a treatment for low to intermediate-1 risk myelodysplastic syndromes (MDS), in 2023 after favorable Phase 3 trial results.

A new molecular scoring system promises to improve the treatment of a set of blood cancers called myelodysplastic syndromes (MDS), according to an international team of researchers. The findings were ...

SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...